SenesTech, Inc. reported its financial results for the third quarter of 2025, revealing a net revenue of $690,000, a 43% increase from $482,000 in the same period last year. For the nine months ending September 30, 2025, the company generated $1.8 million in revenue, up 33% from $1.4 million in the prior year. The growth was primarily driven by the sales of its Evolve product line, which accounted for approximately 85% of third-quarter revenues, compared to 69% in the previous year. Despite the revenue increase, the company reported a net loss of $1.3 million for the quarter, a slight improvement from a loss of $1.5 million in Q3 2024.
In terms of operational changes, SenesTech has focused on expanding its product offerings and market reach. The Evolve product line, which includes Evolve Rat and Evolve Mouse, has seen significant adoption since its launch in January 2024. The company has also made strides in regulatory approvals, with Evolve Mouse receiving additional state registrations during the quarter. The company’s total assets increased to $14.6 million as of September 30, 2025, up from $3.3 million at the end of 2024, largely due to successful financing activities.
SenesTech's operating expenses for the third quarter were $1.8 million, a decrease from $1.9 million in the same quarter of 2024. Research and development expenses fell to $400,000 from $451,000 year-over-year, reflecting cost containment efforts. Selling, general, and administrative expenses remained relatively stable at $1.4 million. The company’s accumulated deficit reached $140.7 million, indicating ongoing challenges in achieving profitability.
The company has also reported a significant increase in cash and cash equivalents, which rose to $7.3 million from $1.3 million at the end of 2024. This increase was bolstered by net proceeds of $13.1 million from financing activities, including the exercise of warrants and the issuance of common stock. SenesTech believes that its current cash position will be sufficient to fund operations for the next 12 months, although it acknowledges the potential need for additional financing to support ongoing losses and research and development efforts.
Looking ahead, SenesTech aims to capitalize on the growing market for non-poison rodent control solutions, driven by increasing regulatory restrictions on traditional rodenticides. The company plans to continue expanding its Evolve product line and enhancing its marketing and sales strategies to achieve sustainable revenue growth. However, it remains cautious about the future, noting that without adequate financing or significant revenue growth, it may face challenges in continuing operations.
About SenesTech, Inc.
Senestech, Inc. develops and commercializes non-lethal fertility control products for managing rodent populations, primarily rats and mice. Its key offerings, ContraPest and Evolve, target reproductive systems to reduce pest numbers sustainably. The company operates in the pest management industry, emphasizing environmentally safe, minimally invasive solutions that complement integrated pest management programs, with a focus on regulatory compliance and market adoption.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.